Katie Hullock

Katie Hullock

Auto-generated profile, based on publicly available information

Katie Hullock

ScHARR, The University of Sheffield, Sheffield, South Yorkshire, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2022 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Open access
PDF file
SWSophie T. Williams
Sophie T. Williams
GWGreg Wells
Greg Wells
SCSamantha Conroy
Samantha Conroy
HGHannah Gagg
Hannah Gagg
RARichard Allen
Richard Allen
SDSarah Danson
Sarah Danson
Despite advances in cancer genomics and the increased use of genomic medicine, metastatic cancer is still mostly an incurable and fatal disease. With diminishing returns from traditional drug discovery strategies, and high clinical failure rates, more emphasis is being placed on alternative drug discovery platforms, such as ex vivo approaches. Ex vivo approaches aim to embed biological relevance and inter-patient variability at an earlier stage of drug discovery, and to offer more precise treatment stratification for patients. However, these techniques also have a high potential to offer personalised therapies to patients, complementing and enhancing genomic medicine. Although an array of approaches are available to researchers, only a minority of techniques have made it through to direct patient treatment within robust clinical trials. Within this review, we discuss the current challenges to ex vivo approaches within clinical practice and summarise the contemporary literature which has directed patient treatment. Finally, we map out how ex vivo approaches could transition from a small-scale, predominantly research based technology to a robust and validated predictive tool. In future, these pre-clinical approaches may be integrated into clinical cancer pathways to assist in the personalisation of therapy choices and to hopefully improve patient experiences and outcomes.

2 October 2024 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
KBK. Biggs
K. Biggs
KHK. Hullock
K. Hullock
CDC. Dix
C. Dix
JLJa. Lane
Ja. Lane
HGH. Green
H. Green
CCC. Cooper
C. Cooper
Background: It is important to design clinical trials to include all those who may benefit from the intervention being tested. Several frameworks have been developed to help researchers think about the barriers to inclusion of particular under-served groups when designing a trial, but there is a lack of practical guidance on how to implement these frameworks. This paper describes the ACCESS project, the findings from each phase of the project and the guidance we developed (STEP UP) on how to design more inclusive trials. Methods: Development of the STEP UP guidance had five phases: (1) Scoping literature review, (2) ‘roundtable’ discussion meetings, (3) redesign of trials, (4) interviews and (5) guidance document development, with input from public contributors and the ACCESS team. Results: Over 40 experts contributed to the ACCESS project—patients and the public, clinicians, NHS research staff, trialists and other academics. The scoping review identified several strategies being used to improve inclusion, mostly around recruitment settings, but there was little evaluation of these strategies. The ‘roundtable’ discussions identified additional strategies being used across the UK and Ireland to improve inclusion, which were grouped into: Communication, Community engagement, Recruitment sites, Patient information, Flexibility, Recruitment settings, Consent process, Monitoring, Training for researchers and Incentives. These strategies were used to redesign three existing trials by applying one of the three INCLUDE frameworks (ethnicity, socioeconomic disadvantage, impaired capacity to consent) to one trial each, to produce the key recommendations for the guidance. Issues around implementation were explored in stakeholder interviews and key facilitators were identified: funders requesting information on inclusion, having the time and funding to implement strategies, dedicated staff, flexibility in trial protocols, and considering inclusion of under-served groups at the design stages. The STEP UP guidance is freely available at http://step-up-clinical-trials.co.uk. Conclusion: Researchers should consider inclusivity to shape initial trial design decisions. Trial teams and funders need to ensure that trials are given both the resources and time needed to implement the STEP UP guidance and increase the opportunities to recruit a diverse population.

5 February 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
GBGavin Brittain
Gavin Brittain
JPJennifer Petrie
Jennifer Petrie
KDKate E M Duffy
Kate E M Duffy
RGRachel Glover
Rachel Glover
KHKatie Hullock
Katie Hullock
JSJohn A Snowden
John A Snowden
Introduction Autologous haematopoietic stem cell transplantation (aHSCT) is increasingly used as treatment for patients with active multiple sclerosis (MS), typically after failure of disease-modifying therapies (DMTs). A recent phase III trial, ‘Multiple Sclerosis International Stem Cell Transplant, MIST’, showed that aHSCT resulted in prolonged time to disability progression compared with DMTs in patients with relapsing remitting MS (RRMS). However, the MIST trial did not include many of the current high-efficacy DMTs (alemtuzumab, ocrelizumab, ofatumumab or cladribine) in use in the UK within the control arm, which are now offered to patients with rapidly evolving severe MS (RES-MS) who are treatment naïve. There remain, therefore, unanswered questions about the relative efficacy and safety of aHSCT over these high-efficacy DMTs in these patient groups. The StarMS trial (Autologous Stem Cell Transplantation versus Alemtuzumab, Ocrelizumab, Ofatumumab or Cladribine in Relapsing Remitting Multiple Sclerosis) will assess the efficacy, safety and long-term impact of aHSCT compared with high-efficacy DMTs in patients with highly active RRMS despite the use of standard DMTs or in patients with treatment naïve RES-MS. Methods and analysis StarMS is a multicentre parallel-group rater-blinded randomised controlled trial with two arms. A total of 198 participants will be recruited from 19 regional neurology secondary care centres in the UK. Participants will be randomly allocated to the aHSCT arm or DMT arm in a 1:1 ratio. Participants will remain in the study for 2 years with follow-up visits at 3, 6, 9, 12, 18 and 24 months postrandomisation. The primary outcome is the proportion of patients who achieve ‘no evidence of disease activity’ during the 2-year postrandomisation follow-up period in an intention to treat analysis. Secondary outcomes include efficacy, safety, cost-effectiveness and immune reconstitution of aHSCT and the four high-efficacy DMTs. Ethics and dissemination The study was approved by the Yorkshire and Humber—Leeds West Research Ethics Committee (20/YH/0061). Participants will provide written informed consent prior to any study specific procedures. The study results will be submitted to a peer-reviewed journal and abstracts will be submitted to relevant national and international conferences. Trial registration number ISRCTN88667898.

1 September 2025 in Health Expectations
Verified
Journal Article
Open access
KHKatie Hullock
Katie Hullock
AOAlicia O'CAthain
Alicia O'CAthain
FSFiona Sampson
Fiona Sampson
JWJonathan Woodward
Jonathan Woodward
ECElizabeth Coates
Elizabeth Coates
CMChristopher McDermott
Christopher McDermott
Objective: To explore intervention fidelity and experiences of using a new intervention designed to optimise calorie intake in people with amyotrophic lateral sclerosis (ALS). Methods: A mixed‐methods process evaluation was conducted alongside an ongoing randomised controlled trial across 15 ALS specialist centres in the United Kingdom. Data collection included 146 healthcare professional‐completed fidelity checklists, audio recordings of 5 intervention sessions, and qualitative interviews with 32 healthcare professionals, patients and informal caregivers. Results: Intervention fidelity was high (88%: 1059/1204 items completed by healthcare professionals). Healthcare professionals, patients and informal caregivers within the sample recognised the intervention's value and engaged with it. Patients were motivated to use the intervention because they believed it could slow disease progression, and it gave them a sense of control. Despite challenges with the intervention, including patient concerns about weight gain and physical limitations in food preparation and consumption, patients in this sample remained committed to using the intervention. However, healthcare professionals suggested that these challenges may have negatively influenced trial recruitment and retention. Caregivers played a crucial role in supporting patients emotionally and physically, helping them to adhere to the intervention. Conclusions: The intervention was feasible to implement and was delivered with fidelity. While patient engagement in this sample was strong, the intervention usability may be time‐limited as physical function declines. Therefore, the intervention may be best suited for those with slower‐progressing ALS who can manage the intervention and dietary changes. Moving forward, continued evaluation is needed to assess effectiveness and explore subgroup differences based on ALS type (slow vs. fast progressing). PPIE Contribution: PPI was integral to the process evaluation. PPI members reviewed key study documents, including the Participant Information Sheet and consent forms, leading to participant materials that were clear and easily understood. They also participated in developing the intervention. Trial Registration: IRAS ID 275949, ISRCTN30588041.

9 December 2024 in Future Healthcare Journal
Verified
Journal Article
Open access
MMMohamed Morgan
Mohamed Morgan
OHOscar Han
Oscar Han
KHKatie Hullock
Katie Hullock
SPSteve Pagden
Steve Pagden
MRMair Richards
Mair Richards
RFRachel Foster
Rachel Foster
This paper addresses a timely and significant issue in the context of the COVID-19 pandemic. Contact tracing played a crucial role in reducing transmission rates. The challenges faced in inpatient settings are valuable to explore. A pilot study involving medical students revealed gaps in engagement with the NHS Test and Trace service. An Inpatient Contact Tracing Team (IPCT) was formed to address this issue. Medical students later assisted in contact tracing. The study was conducted from September to November 2021 and involved 305 inpatients with COVID-19. This initiative demonstrates the benefits of involving medical students in inpatient contact tracing for public health gain and education. The students also engaged in community initiatives, addressing barriers to vaccination in disadvantaged areas. A demographic analysis revealed patterns which guided vaccine education efforts by the IPCT. This collaboration between healthcare professionals and medical students showcases the adaptability of medical education in the face of global health challenges.

26 October 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
SOSally Ohlsen
Sally Ohlsen
DADion Anderson
Dion Anderson
ABAnastasios Bastounis
Anastasios Bastounis
KBKamaldeep Bhui
Kamaldeep Bhui
ABAndrew Booth
Andrew Booth
SWScott Weich
Scott Weich
Introduction Complex emotions include difficulties with emotional regulation, impulsivity, identity, relationships and functioning. These experiences are often construed as borderline personality disorder, a highly stigmatised diagnosis. We will use a transdiagnostic approach to investigate the nature, course and lived experience of complex emotions, with lived experience involvement embedded throughout the programme. We aim to (1) model symptom and functional trajectories to identify subgroups with distinct needs; (2) elucidate mechanisms underlying outcomes, including interactions with social, cultural and environmental factors; (3) investigate associations between complex emotions and physiological and behavioural measures; and (4) integrate findings to inform interventions and service delivery. Methods and analysis We will undertake a mixed methods longitudinal study co-developed with our Lived Experience Advisory Panel (LEAP) and informed by evidence synthesis. We aim to recruit 300 participants who self-identify as experiencing complex emotions through health services, third-sector organisations and probation services, with baseline assessments and 6 monthly follow-up. Two nested substudies will comprise (1) longitudinal biographical interviews and (2) ecological momentary assessment (EMA) of experiential, physiological and behavioural data. Quantitative data will be analysed using multivariate and longitudinal trajectory modelling methods to identify underlying dimensions and phenotypic subgroups. Qualitative data will undergo reflexive thematic and narrative approaches to identify shared experiences, coping strategies and meaning-making. EMA data will be analysed using network and time-series approaches to examine within-person and between-person associations and temporal instability. Findings will be integrated to develop an overall understanding of the nature, trajectories and mechanisms of complex emotions. Ethics and dissemination The cohort and qualitative studies were approved by the East Midlands (Derby) National Health Service (NHS) Research Ethics Committee (REC) and the Health Research Authority (HRA) (IRAS 353789, REC 25/EM/0128; 4 July 2025). The EMA substudy was approved by Cambridge East NHS REC and HRA (IRAS 364085, REC 26/EE/0171; 11 August 2026). Dissemination strategies will be co-developed by researchers, LEAP members and lived experience co-investigators. All partners will contribute to peer-reviewed publications, conference presentations and accessible outputs. The anticipated date of study completion is 31 March 2029.